Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  HIV Infection

  Free Subscription


Articles published in Antivir Ther

Retrieve available abstracts of 33 articles:
HTML format



Single Articles


    June 2022
  1. MUSENGIMANA G, Tuyishime E, Kiromera A, Malamba SS, et al
    Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Antivir Ther. 2022;27:13596535221102690.
    PubMed     Abstract available


    April 2022
  2. LEE WA, Cheng AK
    Tenofovir alafenamide fumarate.
    Antivir Ther. 2022;27:13596535211067600.
    PubMed     Abstract available


  3. ABDOOL KARIM SS, Baxter C, Abdool Karim Q
    Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
    Antivir Ther. 2022;27:13596535211067589.
    PubMed     Abstract available


  4. CHOUDHARY MC, Mellors JW
    The transformation of HIV therapy: One pill once a day.
    Antivir Ther. 2022;27:13596535211062396.
    PubMed     Abstract available


  5. ALTON G, Samuel C, Reddi A
    Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case.
    Antivir Ther. 2022;27:13596535211068617.
    PubMed     Abstract available


  6. SCHINAZI RF, Patel D, Ehteshami M
    The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.
    Antivir Ther. 2022;27:13596535211067599.
    PubMed     Abstract available


  7. YANG T, Oliyai R, Kent KM
    The making of the one pill-Developing single tablet regimens for HIV and for HCV.
    Antivir Ther. 2022;27:13596535211067606.
    PubMed     Abstract available


    November 2021
  8. MOLINA JM, Ene L, Cahn P, Fatkenheuer G, et al
    Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
    Antivir Ther. 2021;26.
    PubMed     Abstract available


  9. RIVERA AS, Machenry S, Okpokwu J, Olatunde B, et al
    HBV co-infection is associated with persistently elevated liver stiffness measurement in HIV-positive adults: A 6-year single-centre cohort study in Nigeria.
    Antivir Ther. 2021;26.
    PubMed     Abstract available


  10. PRESSIAT C, Dainguy E, Treluyer JM, Yonaba C, et al
    Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus.
    Antivir Ther. 2021;26.
    PubMed     Abstract available


    May 2021
  11. MAGGIOLO F, Gianotti N, Comi L, Di Filippo E, et al
    Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
    Antivir Ther. 2021;26.
    PubMed     Abstract available


  12. SCHEIBE K, Urbanska A, Jakubowski P, Hlebowicz M, et al
    Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Antivir Ther. 2021;26.
    PubMed     Abstract available


  13. FARINACCI D, Ciccullo A, Lombardi F, Moschese D, et al
    Evaluation of doravirine-based regimen population target in a large Italian clinical center.
    Antivir Ther. 2021;26.
    PubMed     Abstract available


  14. CICCULLO A, Baldin G, Borghetti A, Di Giambenedetto S, et al
    Real-life findings on the impact of the COVID-19 pandemic on HIV care.
    Antivir Ther. 2021;26.
    PubMed    


    April 2021
  15. LIPINSKI J, Margevicius S, Schluchter MD, Wilson DL, et al
    Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy.
    Antivir Ther. 2021 Apr 26. doi: 10.3851/IMP3389.
    PubMed     Abstract available


  16. JIAMSAKUL A, Azwa I, Zhang F, Yunihastuti E, et al
    Treatment modification after second-line failure among people living with HIV in the Asia-Pacific.
    Antivir Ther. 2021 Apr 12. doi: 10.3851/IMP3388.
    PubMed     Abstract available


    March 2021
  17. YIN MT, Bucovsky M, Williams J, Brunjes D, et al
    Effect of Vitamin D3 and calcium carbonate supplementation on muscle strength in postmenopausal women living with HIV.
    Antivir Ther. 2021 Mar 11. doi: 10.3851/IMP3386.
    PubMed     Abstract available


  18. DORWARD J, Gbinigie O, Cai T, Roberts NW, et al
    The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.
    Antivir Ther. 2021 Mar 11. doi: 10.3851/IMP3385.
    PubMed     Abstract available


    January 2021
  19. ALEJOS B, Suarez-Garcia I, Bernardino JI, Blanco JR, et al
    Effectiveness and safety of antiretroviral treatment in pre- and postmenopausal women living with HIV in a multicentre cohort.
    Antivir Ther. 2021 Jan 20. doi: 10.3851/IMP3380.
    PubMed     Abstract available


  20. LEZCANO CARDUZ VP, Alba NA, Almagro EG, Pernaute OS, et al
    Cytomegalovirus infection associated with severe intraocular inflammation in an HIV patient: a case report.
    Antivir Ther. 2021 Jan 20. doi: 10.3851/IMP3381.
    PubMed     Abstract available


  21. BIJKER R, Kumarasamy N, Kiertiburanakul S, Pujari S, et al
    An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia.
    Antivir Ther. 2021 Jan 19. doi: 10.3851/IMP3379.
    PubMed     Abstract available


  22. POST FA, Hamzah L
    Correcting eGFR for the effects of ART on tubular creatinine secretion: does one size fit all?
    Antivir Ther. 2021 Jan 18. doi: 10.3851/IMP3378.
    PubMed     Abstract available


  23. FLORIDIA M, Masuelli G, Tassis B, Franceschetti L, et al
    Weight gain during pregnancy in women with HIV receiving different antiretroviral regimens.
    Antivir Ther. 2021 Jan 15. doi: 10.3851/IMP3376.
    PubMed     Abstract available


  24. KOUAME GM, Gabillard D, Moh R, Badje A, et al
    Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4(+) cell counts.
    Antivir Ther. 2021;26.
    PubMed     Abstract available


  25. LEE JE, Lee SO, Heo J, Kim DW, et al
    Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
    Antivir Ther. 2021;26.
    PubMed     Abstract available


  26. UGARTE A, De la Mora L, Martinez-Rebollar M, Mallolas J, et al
    An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide-induced cholestasis.
    Antivir Ther. 2021;26.
    PubMed    


    November 2020
  27. BRUNET L, Wyatt C, Hsu R, Mounzer K, et al
    Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals.
    Antivir Ther. 2020 Nov 19. doi: 10.3851/IMP3373.
    PubMed     Abstract available


    September 2020
  28. PILLAY T, Cornell M, Fox MP, Euvrard J, et al
    Recording of HIV viral loads and viral suppression in South African patients receiving antiretroviral treatment: a multicentre cohort study.
    Antivir Ther. 2020 Sep 22. doi: 10.3851/IMP3371.
    PubMed     Abstract available


    June 2020
  29. ZHANG Q, Li X, Qiao S, Shen Z, et al
    Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China.
    Antivir Ther. 2020 Jun 1. doi: 10.3851/IMP3360.
    PubMed     Abstract available


    April 2020
  30. BLACKMAN AL, Heil EL, Devanathan AS, Pandit NS, et al
    The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
    Antivir Ther. 2020 Apr 28. doi: 10.3851/IMP3355.
    PubMed     Abstract available


  31. HOFFMANN C, Schewe K, Fenske S, Buhk T, et al
    Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
    Antivir Ther. 2020 Apr 1. doi: 10.3851/IMP3351.
    PubMed     Abstract available


    March 2020
  32. ARENAS-PINTO A, Stohr W, Khoo S, Clarke A, et al
    Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.
    Antivir Ther. 2020 Mar 23. doi: 10.3851/IMP3340.
    PubMed     Abstract available


    February 2020
  33. BARANEK B, Wang S, Cheung AM, Mishra S, et al
    The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.
    Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: